Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendavia for Ischemia Reperfusion Injury in ARAS
NCT01755858Phase 2Terminated
- Sponsor
- Stealth BioTherapeutics
- Start
- Dec 2012
- Primary completion
- Dec 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemia-reperfusion injury (IRI) comparing Bendavia with Placebo (2 arms). Primary endpoint: Glomerular Filtration Rate at 8 weeks. Started Dec 2012; status: terminated.
02
Drugs
elamipretide
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01755858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01755858.